NDA 204026 · Bristol
Pomalyst
Pomalidomide · Oral · Thalidomide Analog
NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Apr 27, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2013
Feb 8, 2013
Approved uses
5
Original approval plus efficacy supplements
Registered trials
314
56 Phase 3, 58 recruiting
FAERS reports
103,640
63,661 serious, 14,174 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: EMBRYO-FETAL TOXICITY and VENOUS AND ARTERIAL THROMBOEMBOLISM WARNING: EMBRYO-FETAL TOXICITY and VENOUS AND ARTERIAL THROMBOEMBOLISM See full prescribing information for complete boxed warning EMBRYO-FETAL TOXICITY • POMALYST is contraindicated in pregnancy. POMALYST is a thalidomide analogue. Thalidomide is a known human teratogen that causes severe life-threatening birth defects ( 4 , 5.1 , 8.1 ). • For females of reproductive potential: Exclude pregnancy before start of treatment. Prevent pregnancy during treatment by the use of 2 reliable methods of contraception ( 5.1 , 8.3 ). POMALYST is available only through a restricted program called PS-Pomalidomide REMS ( 5.2 ). VENOUS AND ARTERIAL THROMBOEMBOLISM • Deep venous thrombosis (DVT), pulmonary embolism (PE), myocardial infarction, and stroke occur in patients with multiple myeloma treated with POMALYST. Antithrombotic...
What it is approved for
From the label in effect Feb 26, 2025.
POMALYST is a thalidomide analogue indicated for the treatment of adult patients: • in combination with dexamethasone, for patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy ( 1.1 ). • with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART) or in patients with KS who are HIV-negative. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s) ( 1.2 ). 1.1 Multiple Myeloma POMALYST, in combination with dexamethasone, is indicated for adult patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy. 1.2 Kaposi Sarcoma POMALYST is indicated for the treatment of: • Adult patients with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART). • Kaposi sarcoma (KS) in adult patients who are HIV-negative. This indication is approved under accelerated approval based on overall response rate [see Clinical Studies (14.2) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Mechanism: Pomalidomide is an analogue of thalidomide with immunomodulatory, antiangiogenic, and antineoplastic properties. Cellular activities of pomalidomide are mediated through its target cereblon, a component of a cullin ring E3 ubiquitin ligase enzyme complex. In vitro, in the presence of drug, substrate proteins (including Aiolos and Ikaros) are targeted for ubiquitination and subsequent degradation leading to direct cytotoxic and immunomodulatory effects. In in vitro cellular assays, pomalidomide inhibited proliferation and induced apoptosis of hematopoietic tumor cells. Additionally,...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 20, 2020 Supplement 27 · Efficacy · priority review LetterLabel
- May 14, 2020 Supplement 23 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
- May 14, 2020 Supplement 24 · Efficacy · priority review OrphanLabelLetter
- Apr 23, 2015 Supplement 6 · Efficacy OrphanLetterLabel
- Feb 8, 2013 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanReviewLetterLabel
4 products under this application
- POMALYST · POMALIDOMIDE 3MG · CAPSULE, ORAL · Prescription · TE AB
- POMALYST · POMALIDOMIDE 1MG · CAPSULE, ORAL · Prescription · TE AB
- POMALYST · POMALIDOMIDE 4MG · CAPSULE, ORAL · Prescription · TE AB
- POMALYST · POMALIDOMIDE 2MG · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Pomalidomide" as an intervention, any sponsor and status, largest first.
- A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)Pivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07222761 · 915 participants (planned) · Start Jan 2, 2026 · Primary completion May 21, 2029
Drug: Linvoseltamab; Carfilzomib and 4 more · For: Relapsed and/or Refractory Multiple Myeloma (RRMM)
Sites: Atlanta, Georgia; Ann Arbor, Michigan; New York, New York · 60 sites in all
- A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other TreatmentsPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT05020236 · 893 participants (planned) · Start Oct 4, 2021 · Primary completion Feb 26, 2026
Drug: Elranatamab; Daratumumab and 2 more · For: Multiple Myeloma
Sites: Clovis, California; Fresno, California; Fort Collins, Colorado · 237 sites in all
- A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to TreatmentPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05455320 · 864 participants · Start Oct 13, 2022 · Primary completion Jul 30, 2027
Drug: Talquetamab; Daratumumab and 2 more · For: Multiple Myeloma
Sites: Tucson, Arizona; Little Rock, Arkansas; Norwalk, Connecticut · 216 sites in all
- A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and LenalidomidePivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06208150 · 838 participants · Start Jan 22, 2024 · Primary completion Apr 1, 2026
Drug: Talquetamab; Pomalidomide and 4 more · For: Multiple Myeloma
Sites: Clovis, California; Santa Monica, California; New Haven, Connecticut · 242 sites in all
- A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)Pivotal-lookingRecruiting
CelgeneBristol Myers Squibb (BMY)
NCT05519085 · 810 participants (planned) · Start Sep 20, 2022 · Primary completion Jan 10, 2027
Drug: mezigdomide; Pomalidomide and 2 more · For: Relapsed or Refractory Multiple Myeloma
Sites: Los Alamitos, California; San Diego, California; West Hollywood, California · 266 sites in all
- Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple MyelomaPivotal-lookingCompleted
CelgeneBristol Myers Squibb (BMY)
NCT01712789 · 682 participants · Start Nov 6, 2012 · Primary completion Dec 11, 2019
Drug: Pomalidomide; Dexamethasone · For: Multiple Myeloma
Sites: Graz, Austria; Innsbruck, Austria; Vienna, Austria · 112 sites in all
- A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple MyelomaPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05572515 · 614 participants · Start Mar 29, 2023 · Primary completion Oct 13, 2025
Drug: Teclistamab; Pomalidomide and 3 more · For: Multiple Myeloma
Sites: Anchorage, Alaska; Gilbert, Arizona; Berkeley, California · 211 sites in all
AbbVieAbbVie (ABBV)
NCT06892522 · 602 participants (planned) · Start Jun 30, 2025 · Primary completion Dec 2035
Drug: Etentamig; Lenalidomide and 9 more · For: Multiple Myeloma
Sites: Duarte, California; Irvine, California; San Francisco, California · 36 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- plasma cell myeloma8,169
- death7,797
- fatigue7,599
- pneumonia6,387
- off label use4,625
- diarrhoea3,966
- white blood cell count decreased3,709
- neutropenia3,391
- rash3,107
- dyspnoea2,887
- asthenia2,718
- constipation2,705
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2011 | 2 |
| 2012 | 6 |
| 2013 | 1,217 |
| 2014 | 2,659 |
| 2015 | 5,383 |
| 2016 | 5,867 |
| 2017 | 6,831 |
| 2018 | 7,077 |
| 2019 | 9,195 |
| 2020 | 10,066 |
| 2021 | 13,133 |
| 2022 | 11,306 |
| 2023 | 8,275 |
| 2024 | 8,960 |
| 2025 | 8,607 |
| 2026 | 5,056 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Pomalyst (Pomalidomide)
2024 spending
$2.15B
Beneficiaries
14,325
98,648 claims
Per beneficiary
$150,103
$1,094.75 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,453,860,767 |
| 2021 | $1,595,079,245 |
| 2022 | $1,743,892,720 |
| 2023 | $1,709,288,465 |
| 2024 | $2,150,231,815 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.
Costa LJ, Bahlis NJ, Perrot A, et al. · N Engl J Med 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma.
Dimopoulos MA, Beksac M, Pour L, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study.
Ailawadhi S, pička I, Spencer A, et al. · J Clin Oncol 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
- Talquetamab-Daratumumab in Relapsed or Refractory Myeloma.
Mina R, Beksac M, Rodríguez-Otero P, et al. · N Engl J Med 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Pomalidomide for Epistaxis in Hereditary Hemorrhagic Telangiectasia.
Al-Samkari H, Kasthuri RS, Iyer VN, et al. · N Engl J Med 2024 · Clinical Trial, Phase II, Multicenter Study
- Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy.
Touzeau C, Mina R, Quach H, et al. · N Engl J Med 2026 · Randomized Controlled Trial, Multicenter Study
Sponsor: Bristol Myers Squibb
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.